Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: $Mogul who wrote (63080)	9/24/1999 1:21:00 PM
From: kendall harmon	Read Replies (1) \| Respond to of 120523

ARNX might see buying this afternoon ARNX ..12:47 est. Sept 24, 1999 - (Dayinvestor.com - Update): ARNX - 4 7/16 x 4 1/2 - Investors eagerly await NYOTRAN (R) phase III data being presented this weekend. Data from phase III clinical trial will be presented Sunday, September 26, 1999 in "late breaker session" at 39th Interscience Conference on Antimicrobial Agents and Chemotherapy meeting. Aronex Chairman and CEO Geoffrey Cox estimates sales potential of $150M-$200M within 4 to 5 years for new systemic fungal infection drug. Abbott Laboratories (NYSE: ABT) is drug marketing partner. Source: techstocks.com